Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 19, 2007 - Issue sup1
131
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Risk Assessment for Biopersistent Granular Particles

&
Pages 199-204 | Received 17 Aug 2006, Accepted 01 Nov 2006, Published online: 20 Oct 2008
 

Abstract

In 1997 the German MAK-Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area established a “general threshold value” of 4 mg/m3 for the inhalable fraction and 1.5 mg/m3 for the respirable fraction of poorly soluble dusts. The “general threshold value” is to apply for dusts for which no specific MAK value exists. This value is based on data from epidemiological studies with the target criterion being the impairment of lung function as well as on data from long-term experimental studies with rats with the target criterion being the reduction in the rate of alveolar clearance. Thereby, the deposition of 1 μl dust/g lung is seen as the threshold value. In recent years several studies have shown tumorigenic responses of rats after exposure to poorly soluble low-toxicity particles. The MAK Commission together with members of the subcommittee III of the Committee on Hazardous Substances (AGS) is currently reevaluating the toxic effects of granular dusts, known as poorly soluble low-toxicity particles (PSP). The target is to evaluate the mode of action for tumor induction and to determine the most sensitive parameters that trigger these effects. Since induction of inflammation is seen as the underlying mechanism, the commission is presently evaluating the parameters that indicate an inflammatory response of the airway system in order to identify a no-observed-adverse-exposure level (NOAEL), which can then be used to establish an MAK value. In this case biopersistent granular particles would be classified in Category 4, for carcinogenic substances for which genotoxic effects play no or at most a minor part. Provided the MAK value is observed, no significant contribution to human cancer is expected.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.